CYTK250117C23000
- 0.00
- 0.000.00%
Cytokinetics Newsroom
Cytokinetics Analyst Ratings
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $62
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $82
Cytokinetics Is Maintained at Outperform by RBC Capital
Cytokinetics Analyst Ratings
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $62 to $120
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Cytokinetics Analyst Ratings
Promising Prospects for Cytokinetics: Aficamten's Strong Phase 3 Results and Strategic Bayer Collaboration Drive Buy Rating
RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)
Cytokinetics Is Maintained at Outperform by Mizuho
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120
Cytokinetics' Hold Rating Amid Bayer Partnership and Acquisition Uncertainty